DE60006618D1 - Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten - Google Patents

Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten

Info

Publication number: DE60006618D1
Authority: DE; Germany
Prior art keywords: azepines; tetrahydrobenzo; receptor antagonists; glutamate receptor; metabotropic glutamate
Prior art date: 1999-08-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE60006618T

Other languages

English (en)

Other versions

DE60006618T2 (de

Inventor

Geo Adam

Alfred Binggeli

Hans-Peter Maerki

Vincent Mutel

Maurice Wilhelm

Wolfgang Wostl

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

F Hoffmann La Roche AG

Original Assignee

F Hoffmann La Roche AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-06

Filing date

2000-07-27

Publication date

2003-12-24

2000-07-27 Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG

2003-12-24 Application granted granted Critical

2003-12-24 Publication of DE60006618D1 publication Critical patent/DE60006618D1/de

2004-09-23 Publication of DE60006618T2 publication Critical patent/DE60006618T2/de

2020-07-28 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

DE60006618T 1999-08-06 2000-07-27 Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten Expired - Fee Related DE60006618T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP99115557		1999-08-06
EP99115557		1999-08-06

Publications (2)

Publication Number	Publication Date
DE60006618D1 true DE60006618D1 (de)	2003-12-24
DE60006618T2 DE60006618T2 (de)	2004-09-23

Family

ID=8238742

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60006618T Expired - Fee Related DE60006618T2 (de)	1999-08-06	2000-07-27	Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten

Country Status (27)

Country	Link
US (1)	US6218385B1 (de)
JP (1)	JP3260350B2 (de)
KR (1)	KR100390116B1 (de)
CN (1)	CN1146455C (de)
AR (1)	AR025035A1 (de)
AT (1)	ATE254614T1 (de)
AU (1)	AU774485B2 (de)
BR (1)	BR0003375A (de)
CA (1)	CA2314798A1 (de)
CO (1)	CO5180625A1 (de)
DE (1)	DE60006618T2 (de)
ES (1)	ES2209728T3 (de)
HR (1)	HRP20000520A2 (de)
HU (1)	HUP0003112A3 (de)
ID (1)	ID26743A (de)
IL (1)	IL137688A0 (de)
MA (1)	MA26748A1 (de)
NO (1)	NO20003966L (de)
NZ (1)	NZ506096A (de)
PE (1)	PE20010467A1 (de)
PL (1)	PL341890A1 (de)
RU (1)	RU2240317C2 (de)
SG (1)	SG93251A1 (de)
TR (1)	TR200002298A3 (de)
UY (1)	UY26276A1 (de)
YU (1)	YU49700A (de)
ZA (1)	ZA200003927B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1345609E (pt) *	2000-12-22	2005-08-31	Hoffmann La Roche	Derivados de tetra-hidro-(benzo ou tieno)-azepina-pirazina como antagonistas de mglur 1
US6953787B2 (en)	2002-04-12	2005-10-11	Arena Pharmaceuticals, Inc.	5HT2C receptor modulators
KR100765027B1 (ko) *	2002-12-20	2007-10-09	글락소 그룹 리미티드	신경 장애 치료용 벤즈아제핀 유도체
JP4782003B2 (ja) *	2003-06-17	2011-09-28	アリーナファーマシューティカルズ，インコーポレイテッド	５ｈｔ２ｃレセプター関連疾患の処置に有用なベンズアゼピン誘導体
EP2189448B1 (de)	2003-06-17	2014-01-29	Arena Pharmaceuticals, Inc.	Prozesse zur Trennung von 3-Benzazepin-Razematen
US20080009478A1 (en) *	2003-10-22	2008-01-10	Arena Pharmaceuticals, Inc.	Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
WO2005042490A1 (en) *	2003-10-22	2005-05-12	Arena Pharmaceuticals, Inc.	Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
SI1838677T1 (sl)	2004-12-21	2010-01-29	Arena Pharm Inc	Kristalne oblike (R)-8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin hidroklorida
AU2005322183B2 (en)	2004-12-23	2012-03-29	Arena Pharmaceuticals, Inc.	5HT2C receptor modulator compositions and methods of use
EP2258357A3 (de)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
CA2620333A1 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
WO2007047978A2 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
EP1942879A1 (de)	2005-10-31	2008-07-16	Braincells, Inc.	Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
JP5199997B2 (ja) *	2006-04-03	2013-05-15	アリーナファーマシューティカルズ，インコーポレイテッド	８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンズアゼピンおよびこれに関連する中間体を調製するためのプロセス
WO2007134077A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 ht receptor mediated neurogenesis
JP2009536669A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	アンジオテンシン調節による神経新生
EP1873527A1 (de) *	2006-06-30	2008-01-02	Schwarz Pharma Ag	Verfahren zur Identifizierung von CRMP-Modulatoren
KR20090064418A (ko)	2006-09-08	2009-06-18	브레인셀즈 인코퍼레이션	4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
ES2610508T3 (es)	2006-11-22	2017-04-27	Clinical Research Associates, Llc	Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
ES2522587T3 (es) *	2006-12-05	2014-11-17	Arena Pharmaceuticals, Inc.	Procesos para preparar (R)-8-cloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzacepina e intermedios de la misma
TW200845978A (en) *	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EP2288585A1 (de)	2008-03-04	2011-03-02	Arena Pharmaceuticals, Inc.	Verfahren zur herstellung von mit dem 5-ht2c-agonisten (r)-8-chlor-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepin verwandten zwischenprodukten
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CN102648170A (zh)	2009-06-18	2012-08-22	艾尼纳制药公司	制备5-ht2c受体激动剂的方法
EP2544688B1 (de)	2010-03-02	2016-09-07	President and Fellows of Harvard College	Verfahren und zusammensetzungen zur behandlung des angelman-syndroms
US20110294879A1 (en)	2010-05-28	2011-12-01	Xenoport, Inc.	Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US9045431B2 (en)	2010-06-02	2015-06-02	Arena Pharmaceuticals, Inc.	Processes for the preparation of 5-HT2C receptor agonists
US20120016021A1 (en)	2010-07-15	2012-01-19	Xenoport, Inc.	Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
CN103347523A (zh)	2010-09-01	2013-10-09	艾尼纳制药公司	向具有肾损伤的个体给药氯卡色林
EP2611782A1 (de)	2010-09-01	2013-07-10	Arena Pharmaceuticals, Inc.	Lorcaserin-salze mit optisch aktiven säuren
KR20130101524A (ko)	2010-09-01	2013-09-13	아레나 파마슈티칼스, 인크.	5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
CN103189053A (zh)	2010-09-01	2013-07-03	艾尼纳制药公司	用于体重控制的5-ht2c激动剂的调节释放剂型
CA2886875A1 (en)	2012-10-09	2014-04-17	Arena Pharmaceuticals, Inc.	Method of weight management

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4206210A (en) *	1977-01-19	1980-06-03	Smithkline Corporation	Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
WO1992007844A1 (en) *	1990-11-06	1992-05-14	Pfizer Inc.	Quinazolines derivatives for enhancing antitumor activity
US5241065A (en) *	1992-02-25	1993-08-31	Schering Corporation	2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity
AU678503B2 (en) *	1993-09-24	1997-05-29	Takeda Chemical Industries Ltd.	Condensed heterocyclic compounds and their use as squalene synthetase inhibitors

2000
- 2000-07-27 ES ES00116091T patent/ES2209728T3/es not_active Expired - Lifetime
- 2000-07-27 AT AT00116091T patent/ATE254614T1/de not_active IP Right Cessation
- 2000-07-27 DE DE60006618T patent/DE60006618T2/de not_active Expired - Fee Related
- 2000-08-01 MA MA26033A patent/MA26748A1/fr unknown
- 2000-08-01 CA CA002314798A patent/CA2314798A1/en not_active Abandoned
- 2000-08-01 US US09/630,702 patent/US6218385B1/en not_active Expired - Fee Related
- 2000-08-01 NZ NZ506096A patent/NZ506096A/xx unknown
- 2000-08-02 PE PE2000000768A patent/PE20010467A1/es not_active Application Discontinuation
- 2000-08-02 ID IDP20000655A patent/ID26743A/id unknown
- 2000-08-02 HR HR20000520A patent/HRP20000520A2/hr not_active Application Discontinuation
- 2000-08-02 ZA ZA200003927A patent/ZA200003927B/xx unknown
- 2000-08-02 SG SG200004344A patent/SG93251A1/en unknown
- 2000-08-02 AU AU48979/00A patent/AU774485B2/en not_active Ceased
- 2000-08-03 CO CO00058410A patent/CO5180625A1/es not_active Application Discontinuation
- 2000-08-03 IL IL13768800A patent/IL137688A0/xx unknown
- 2000-08-04 TR TR2000/02298A patent/TR200002298A3/tr unknown
- 2000-08-04 RU RU2000120522/04A patent/RU2240317C2/ru not_active IP Right Cessation
- 2000-08-04 JP JP2000236848A patent/JP3260350B2/ja not_active Expired - Fee Related
- 2000-08-04 UY UY26276A patent/UY26276A1/es not_active Application Discontinuation
- 2000-08-04 CN CNB001225235A patent/CN1146455C/zh not_active Expired - Fee Related
- 2000-08-04 HU HU0003112A patent/HUP0003112A3/hu unknown
- 2000-08-04 NO NO20003966A patent/NO20003966L/no not_active Application Discontinuation
- 2000-08-04 KR KR10-2000-0045324A patent/KR100390116B1/ko not_active Expired - Fee Related
- 2000-08-04 AR ARP000104022A patent/AR025035A1/es not_active Application Discontinuation
- 2000-08-07 BR BR0003375-8A patent/BR0003375A/pt not_active Application Discontinuation
- 2000-08-07 PL PL00341890A patent/PL341890A1/xx unknown
- 2000-08-07 YU YU49700A patent/YU49700A/sh unknown

Also Published As

Publication number	Publication date
SG93251A1 (en)	2002-12-17
UY26276A1 (es)	2000-10-31
JP3260350B2 (ja)	2002-02-25
DE60006618T2 (de)	2004-09-23
ZA200003927B (en)	2001-02-06
ES2209728T3 (es)	2004-07-01
HUP0003112A3 (en)	2003-07-28
AU774485B2 (en)	2004-07-01
US6218385B1 (en)	2001-04-17
YU49700A (sh)	2003-04-30
TR200002298A2 (tr)	2001-03-21
IL137688A0 (en)	2001-10-31
BR0003375A (pt)	2001-03-13
TR200002298A3 (tr)	2001-03-21
KR20010082510A (ko)	2001-08-30
HUP0003112A2 (hu)	2002-11-28
HRP20000520A2 (en)	2001-06-30
CN1283623A (zh)	2001-02-14
ATE254614T1 (de)	2003-12-15
CO5180625A1 (es)	2002-07-30
PL341890A1 (en)	2001-02-12
KR100390116B1 (ko)	2003-07-04
RU2240317C2 (ru)	2004-11-20
HU0003112D0 (en)	2000-10-28
NO20003966L (no)	2001-02-07
ID26743A (id)	2001-02-08
PE20010467A1 (es)	2001-04-17
NZ506096A (en)	2002-08-28
JP2001089472A (ja)	2001-04-03
AR025035A1 (es)	2002-11-06
AU4897900A (en)	2001-02-08
CN1146455C (zh)	2004-04-21
CA2314798A1 (en)	2001-02-06
NO20003966D0 (no)	2000-08-04
MA26748A1 (fr)	2004-12-20

Publication	Publication Date	Title
DE60006618D1 (de)	2003-12-24	Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten
DE60009116D1 (de)	2004-04-22	Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE60005386D1 (de)	2003-10-23	Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE60015296D1 (de)	2004-12-02	Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
ATE277905T1 (de)	2004-10-15	4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
PL349778A1 (en)	2002-09-09	Tricyclic benzodiazepines as vasopressin receptor antagonists
HUP0301665A3 (en)	2008-12-29	Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
EP1105389A4 (de)	2001-10-17	Integrinreceptorantagonisten
DE69925730D1 (de)	2005-07-14	4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten
DE60114413D1 (de)	2005-12-01	Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
DE60112322D1 (de)	2005-09-01	Aminothiazole und deren verwendung als adenosinrezeptorantagonisten
DE60106607D1 (de)	2004-11-25	Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
DE60129841D1 (de)	2007-09-20	Indolderivate und deren verwendung als 5-ht2b- und 5-ht2c-rezeptorliganden
EP1007051A4 (de)	2001-08-29	Integrin rezeptor antagonisten
EP1229910A4 (de)	2003-10-01	Integrinrezeptorantagonisten
ATE340784T1 (de)	2006-10-15	Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden
AU2001290772A1 (en)	2002-03-26	Alpha v integrin receptor antagonists
EP1027337A4 (de)	2002-04-03	Integrin-rezeptor-antagonisten
EP1248607A4 (de)	2004-10-06	Urotensin-ii rezeptorantagonisten
IL148043A0 (en)	2002-09-12	Novel integrin receptor antagonists
DE60126614D1 (de)	2007-03-29	1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten
GB9820014D0 (en)	1998-11-04	Receptor antagonists and uses thereof
ATE389659T1 (de)	2008-04-15	Benzoxazepinderivate und deren verwendung als stimulatoren des ampa-rezeptors
IL146146A0 (en)	2002-07-25	Integrin receptor antagonists
PL370367A1 (en)	2005-05-16	Ccr-3 receptor antagonists v

Legal Events

Date	Code	Title	Description
2007-04-05	8364	No opposition during term of opposition
2010-05-20	8339	Ceased/non-payment of the annual fee